Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications (Q38050315)

27 August 2017

title

Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications (English)

1 reference

27 August 2017

1 reference

E Ch Yiannakopoulou

1

1 reference

27 August 2017

publication date

9 October 2012

1 reference

The Pharmacogenomics Journal

27 August 2017

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

105-109

1 reference

Pharmacogenomics: translating functional genomics into rational therapeutics

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Methods for analysis in pharmacogenomics: lessons from the Pharmacogenetics Research Network Analysis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

New Pharmacogenomic Paradigm in Breast Cancer Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Cancer pharmacogenomics may require both qualitative and quantitative approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Pharmacogenomics of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Genetic testing in cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Pharmacogenomics in colorectal cancer: the first step for individualized-therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Impact of OATP transporters on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Hepatic drug transporters, old and new: pharmacogenomics, drug response, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Transporters and drug therapy: implications for drug disposition and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Pharmacogenomics of membrane transporters: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Pharmacogenetics of drug transporters and its impact on the pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Genetic causes of clopidogrel nonresponsiveness: which ones really count?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Pharmacogenetics of membrane transporters: an update on current approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Individualized pharmacotherapy with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Pharmacogenomics of human ABC transporter ABCC11 (MRP8): potential risk of breast cancer and chemotherapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Irinotecan pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

In Vitro and In Vivo Evidence of the Importance of Organic Anion Transporters (OATs) in Drug Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.42

21 January 2018

Identifiers

DOI

10.1038/TPJ.2012.42

1 reference

Dimensions Publication ID

27 August 2017

1035327356

0 references

1 reference